PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Irinotecan

Drugs in development · updated 30 October 2026

Irinotecan: clinical trials and development status

Other names and codes: Onivyde, CPT-11, Camptosar

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 14 October 2016

As of 30 October 2026 Irinotecan is in 231 active clinical trials (recruiting or ongoing, phases I–III) for 73 diseases. The most advanced phase is III.

231Active trials
IIIMost advanced phase
73Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Irinotecan and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 73 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Colorectal neoplasmIII54NCT07775287
Pancreatic neoplasmIII28NCT07621718
MetastasisIII21NCT06897644
Stomach neoplasmIII16NCT06346392
NeuroblastomaIII14NCT06172296
NeoplasmIII13NCT04607421
Colonic neoplasmIII11NCT04607421
Rectal neoplasmIII9NCT04607421
RhabdomyosarcomaIII9NCT02567435
Esophageal squamous cell carcinomaIII8NCT06644781
Lung small cell carcinomaIII7NCT06954246
Esophageal neoplasmIII5NCT04415853
Esophagus adenocarcinomaIII4NCT06356311
Gastrointestinal neoplasmIII4NCT04607421
Neuroendocrine carcinomaIII4NCT07595913
Biliary tract neoplasmIII3NCT07606599
CholangiocarcinomaIII3NCT07328919
HepatoblastomaIII3NCT03533582
Appendiceal neoplasmIII2NCT07271355
Digestive system neoplasmIII2NCT04607421
GanglioneuroblastomaIII2NCT06172296
Hepatocellular carcinomaIII2NCT03017326
Intestinal neoplasmIII2NCT04607421
Alveolar rhabdomyosarcomaIII1NCT02567435
Colonic diseaseIII1NCT04607421
Digestive System DiseasesIII1NCT04607421
Embryonal rhabdomyosarcomaIII1NCT02567435
Fibrolamellar hepatocellular carcinomaIII1NCT03533582
Gastrointestinal diseaseIII1NCT04607421
Intestinal diseaseIII1NCT04607421

Everything on Irinotecan

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch